MedTrace Logo

Study of Immune Thrombocytopenia Pathogenesis:

NCT02042560 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 89

Last updated 2018-03-15

No results posted yet for this study

Summary

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet count responsible for bleedings. The disease is mostly mediated by antiplatelet antibodies produced by specific B cells. However, T cells are also involved but their role is not completely understood.

The aim of this study is to determine the implication of T cells in the pathogenesis of ITP, notably regulatory T cells (Treg, CD4+CD25highFoxp3+), cytotoxic T cells (CD3+CD8+) and T follicular helper cells (TFH, CD3+CD4+CXCR5+PD-1+ICOS+), in blood and in the spleen of primary ITP patients, compared to healthy controls.

Conditions

  • Primary Immune Thrombocytopenia (ITP)

Interventions

OTHER

Blood samples

OTHER

Spleen samples

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Dijon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-04
Primary Completion
2015-03-12
Completion
2015-03-12

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02042560 on ClinicalTrials.gov